liver
sampl
obtain
surgic
resect
nontumor
liver
tissu
patient
hcc
patient
solitari
hcc
less
cm
diamet
show
metastasi
lymph
node
organ
quantifi
concentr
liver
follow
normal
ribosom
rna
classifi
sampl
three
group
accord
hcv
load
measur
arbitrari
unit
hcv
rna
high
middl
low
patient
chronic
hepat
liver
cirrhosi
subject
belong
case
group
case
http
liver
sampl
obtain
nontumor
liver
tissu
patient
hepat
metastas
colon
cancer
written
inform
consent
obtain
patient
studi
protocol
previous
approv
ethic
committe
school
accord
declar
helsinki
japanes
fulmin
hepat
isol
hcv
subgenom
replicon
cultur
dulbecco
modifi
eagl
medium
dmem
supplement
fetal
bovin
serum
fb
contain
mgml
invitrogen
carlsbad
ca
respect
human
plasma
phosphoramidon
bestatin
purchas
st
loui
mo
trypsin
porcin
pancrea
baee
unitsmg
soybean
trypsin
inhibitor
sbti
baee
unitsmg
fluorid
hydrochlorid
aebsf
calpain
inhibitor
pepstatin
hp
roch
diagnost
gmbh
mannheim
germani
small
interf
rna
sirna
dharmacon
thermo
fisher
scientif
waltham
rabbit
monoclon
antibodi
ab
abcam
cambridg
uk
secondari
ab
conjug
alexa
fluor
invitrogen
bromid
mtt
purchas
dojindo
kumamoto
japan
summari
messeng
rna
mrna
express
shown
http
five
random
sampl
group
nontumor
liver
tissu
without
liver
cirrhosi
http
analyz
gene
express
profil
also
analyz
gene
express
seven
three
sampl
group
nontumor
liver
tissu
liver
cirrhosi
http
complementari
rna
crna
synthes
total
rna
use
megascript
kit
ambion
austin
tx
fragment
crna
hybrid
human
genom
plu
array
affymetrix
santa
clara
ca
compris
probe
wash
stain
fluidic
station
affymetrix
array
scan
scanner
affymetrix
accord
protocol
describ
affymetrix
genechip
express
analysi
manual
signal
gene
analyz
use
genespr
version
silicon
genet
redwood
ca
http
show
candid
differenti
express
gene
isol
chronic
hepat
liver
sampl
without
liver
cirrhosi
total
rna
isol
liver
tissu
subject
dnase
treatment
follow
cdna
synthesi
describ
synthesi
cdna
cultur
cell
perform
use
total
rna
revertra
ace
qpcr
rt
master
mix
gdna
remov
toyobo
osaka
japan
express
level
specif
mrna
determin
quantit
polymeras
chain
reaction
qpcr
use
sybr
green
taqman
gene
express
assay
primer
sequenc
sybr
green
qpcr
shown
togeth
taqman
gene
express
assay
id
http
thin
section
thick
treat
mm
citrat
buffer
ph
minut
antigen
retriev
block
hydrogen
peroxid
follow
skim
milk
salin
pb
minut
section
incub
ab
minut
stain
histofin
simpl
stain
max
po
multi
nichirei
tokyo
japan
minut
room
temperatur
section
react
dab
chromogen
wako
pure
chemic
industri
ltd
tokyo
japan
counterstain
hematoxylin
hcv
hcvcc
deriv
genotyp
prepar
previous
cell
seed
plate
contain
coverslip
incub
overnight
cell
inocul
hcvcc
copi
hcv
rna
unit
hour
pb
remov
inoculum
cell
incub
complet
medium
day
cultur
coverslip
rins
pb
stain
hcv
protein
alexa
fluor
describ
nuclei
stain
dapi
invitrogen
stain
cell
visual
biorevo
microscop
keyenc
osaka
japan
fluoresc
microscop
olympu
tokyo
japan
hcv
infect
determin
number
foci
contain
cell
cell
number
occasion
decreas
stain
number
foci
normal
total
number
cell
use
area
nuclei
instead
cell
number
cultiv
cell
plate
cell
transfect
nm
sirna
use
dharmafect
cell
cultur
complet
medium
harvest
infect
hcvcc
hour
contain
cdna
encod
human
wt
encod
inact
mutant
digest
ecori
noti
isol
cdna
fragment
insert
ecorinoti
site
vector
contain
gene
invitrogen
vector
use
neg
control
cell
transfect
complex
plasmid
stabl
clone
transfect
cell
establish
cultur
blasticidin
clone
screen
immunofluoresc
stain
ab
secondari
ab
conjug
alexa
fluor
fixat
paraformaldehyd
room
temperatur
minut
serin
proteas
activ
assess
use
follow
synthet
peptid
analog
boc
mca
peptid
institut
inc
osaka
japan
genenet
fukuoka
japan
precultur
cell
hour
black
plate
follow
pb
wash
peptid
substrat
ad
cell
fluoresc
releas
aminomethyl
coumarin
measur
immedi
use
infinit
tecan
schweiz
ag
switzerland
nm
excitationemiss
wavelength
everi
minut
hour
fluoresc
normal
cell
number
determin
mtt
assay
enzym
activ
assess
kinet
specif
inhibit
sbti
manner
http
fusion
assess
describ
stabl
cell
clone
grown
plate
transfect
mixtur
hemagglutinin
ha
subtyp
plasmid
enhanc
green
fluoresc
protein
egfp
plasmid
use
hp
dna
transfect
reagent
day
cell
incub
dmem
absenc
exogen
trypsin
supplement
day
cell
wash
pb
treat
prewarm
buffer
mm
nacl
mm
sodium
citrat
ph
minut
buffer
replac
dmem
contain
fb
cell
incub
hour
cell
observ
use
fluoresc
microscop
percentag
fluoresc
area
measur
use
imagej
softwar
version
nation
institut
health
bethesda
md
u
test
use
analyz
comparison
student
test
use
experi
vitro
p
valu
less
consid
statist
signific
investig
provir
host
respons
hcv
infect
human
liver
use
oligonucleotid
microarray
examin
differenti
gene
express
two
group
liver
sampl
contain
high
low
hcv
load
exclud
involv
variabl
divid
nontumor
liver
tissu
two
group
one
one
without
liver
cirrhosi
obtain
patient
chronic
hepat
earli
stage
hcc
hcv
load
differ
markedli
two
group
clinicopatholog
featur
significantli
differ
accord
statist
analys
http
identifi
candid
gene
liver
chronic
hepat
presenc
absenc
liver
cirrhosi
verifi
gene
liver
high
hcv
load
use
chronic
hepat
liver
without
liver
cirrhosi
http
gene
seven
isg
oasl
isg
unknown
function
inhibit
hcv
replic
vitro
describ
thu
gene
group
relat
antivir
respons
howev
known
whether
sever
gene
associ
provir
respons
function
infect
among
gene
group
http
focus
member
hepsin
hpn
subfamili
type
ii
transmembran
serin
one
top
three
differenti
express
gene
addit
oasl
gene
lowest
p
valu
u
test
show
chang
current
understand
physiolog
function
type
ii
transmembran
serin
proteas
highlight
contribut
human
diseas
seem
import
determin
whether
involv
life
cycl
hcv
pathogenesi
liver
compar
liver
confirm
qpcr
fig
protein
also
highli
express
liver
shown
immunohistochemistri
ihc
local
heterogen
liver
tissu
strongli
posit
apic
membran
hepatocyt
fig
investig
involv
serin
proteas
hcv
infect
vitro
analyz
hcv
infect
inocul
hcvcc
hour
presenc
sever
differ
proteas
inhibitor
follow
remov
inoculum
cultur
day
among
inhibitor
five
class
proteas
serin
proteas
inhibitor
includ
sbti
aebsf
inhibit
infect
manner
fig
confirm
role
serin
proteas
cell
surfac
earli
stage
hcv
infect
hcvcc
inocul
presenc
trypsin
hcv
infect
enhanc
mgml
trypsin
fig
effect
cell
morpholog
determin
step
earli
stage
infect
attach
entri
hcvcc
cell
inhibit
sbti
hcvcc
incub
cell
first
hour
attach
remov
hcvcc
inoculum
cell
incub
hour
allow
entri
fig
cell
incub
day
determin
hcv
infect
stain
cell
even
sbti
present
second
step
entri
hcv
infect
inhibit
fig
hcv
replic
postentri
inhibit
sbti
fig
result
suggest
serin
proteas
involv
earli
stage
infect
particularli
entri
hcvcc
cell
sbti
also
inhibit
hcv
infect
extent
chimer
virus
contain
genotyp
structur
gene
statist
signific
http
ask
type
serin
proteas
express
cell
whether
express
proteas
increas
decreas
hcvcc
infect
determin
mrna
level
transmembran
serin
proteas
postinfect
hcvcc
furin
hpn
express
cell
absent
fig
furin
mrna
infect
hcvcc
fig
hand
normal
human
liver
predominantli
express
four
proteas
hpn
abund
follow
furin
descend
order
http
liver
http
fig
serin
proteas
cell
measur
use
synthet
fluorogen
substrat
contain
variou
amino
acid
sequenc
cleavag
site
fig
highest
proteas
activ
qsr
activ
qar
qrr
fsr
rvrr
similar
level
less
half
qsr
substrat
specif
profil
cell
quit
differ
pancreat
trypsin
fig
knockdown
furin
hpn
respect
sirna
effect
focu
format
infect
cell
http
result
suggest
serin
proteas
furin
hpn
involv
suscept
cell
hcv
infect
investig
whether
involv
hcv
infect
establish
stabl
cell
clone
produc
wt
inact
mutant
fig
b
proteas
clone
specif
activ
substrat
qar
qgr
put
substrat
proteas
control
clone
fig
influenza
viru
ha
introduc
transfect
express
plasmid
cell
clone
ha
induc
fusion
cell
clone
fig
e
fusion
depend
activ
induc
cell
clone
howev
trypsin
treatment
induc
cell
fusion
cell
clone
immunoblot
show
autocleavag
peptid
gener
activ
domain
cell
clone
cell
clone
http
thu
cell
clone
show
function
proteas
activ
synthet
peptid
vitro
nativ
substrat
vivo
hcv
infect
also
enhanc
manner
cell
clone
cell
clone
sensit
hcv
infect
cell
clone
fig
mrna
knock
sirna
proteas
activ
qar
qgr
markedli
reduc
cell
clone
fig
b
proteas
activ
qsr
fsr
also
respond
knockdown
wt
fig
enhanc
hcv
infect
also
reduc
level
neg
control
knockdown
fig
abil
hcv
infect
cell
chang
even
though
mrna
markedli
knock
fig
c
thu
proteas
activ
activ
hcvcc
infect
vitro
found
gene
significantli
elev
nontumor
noncirrhot
liver
chronic
hepat
contain
high
hcv
load
compar
contain
low
hcv
load
http
http
unexpectedli
antivir
gene
rather
highli
express
liver
load
includ
isg
inflammationimmun
gene
gene
exampl
markedli
typic
isg
oasl
http
function
initi
unknown
inhibit
replic
hcvcc
describ
interestingli
transit
emt
notabl
http
activ
emt
state
inhibitori
tight
viral
infect
measl
viru
like
hcv
infect
thu
compar
studi
show
among
two
possibl
host
respons
hcv
infect
provir
respons
antivir
respons
chief
respons
liver
high
hcv
load
antivir
respons
consid
result
high
hcv
load
wherea
provir
respons
caus
high
hcv
load
persist
high
hcv
load
may
caus
unknown
provir
mechan
respons
suffici
reduc
hcv
load
six
gene
includ
isg
overlap
previou
studi
compar
liver
http
gene
first
identifi
studi
use
elucid
mechan
hcv
control
persist
human
liver
gene
whose
role
unknown
hcv
control
persist
remain
describ
ask
quit
significantli
liver
associ
hcv
infect
vitro
demonstr
serin
proteas
involv
earli
stage
hcv
infect
activ
hcvcc
infect
vitro
member
type
ii
transmembran
serin
proteas
activ
proteas
airway
epithelium
influenza
viru
infect
cleav
surfac
glycoprotein
ha
produc
fusion
peptid
facilit
spread
thu
tissu
express
affect
viral
pneumotrop
pathogen
recent
also
shown
contribut
spread
respiratori
virus
sever
acut
respiratori
syndrom
coronaviru
parainfluenza
virus
cleav
viral
spike
protein
f
protein
respect
lead
current
report
use
mice
indic
essenti
influenza
viru
pathogenesi
known
yet
target
protein
hcv
infect
whether
fusion
activ
induc
preferenti
local
apic
membran
hepatocyt
human
liver
high
hcv
load
fig
proteas
activ
detect
surfac
cell
fig
therefor
might
also
involv
hcv
entri
spread
close
tight
junction
hepatocyt
human
liver
compon
occludin
ocln
key
molecul
hcv
entri
hand
cleav
newli
synthes
ha
secretori
pathway
within
influenza
also
play
role
releas
porcin
epidem
diarrhea
determin
whether
activ
occur
earli
stage
hcv
entri
andor
spread
late
stage
hcv
releas
crucial
identifi
protein
cleav
activ
hcv
infect
studi
suggest
possibl
sequenc
target
qar
qgr
sensit
sequenc
examin
fig
qsr
qtr
also
sensit
sequenc
shown
nativ
protein
target
activ
form
gener
autocleavag
qsr
produc
stabli
transfect
cell
manner
http
fusion
occur
use
subtyp
ha
cleavag
site
qtr
fig
e
thu
broadli
activ
sever
sequenc
qxr
qar
qgr
sensit
rvrr
clearli
resist
fig
recent
substrat
character
use
variou
ha
subtyp
subtyp
ha
examin
cleav
vari
survey
sequenc
qe
xr
surfac
protein
lipoviroparticl
host
entri
factor
hcv
infect
identifi
sever
possibl
protein
candid
target
apolipoprotein
apo
b
apo
lipoprotein
receptor
scaveng
receptor
class
b
type
ocln
hcv
fusion
process
depend
ph
lipid
composit
viral
target
membran
hcv
though
remain
unclear
whether
cellular
proteas
requir
identifi
target
help
highlight
novel
activ
mechan
hcv
infect
major
endogen
transmembran
serin
proteas
furin
hpn
involv
infect
cell
hcvcc
http
demonstr
serin
proteas
cell
mainli
activ
qsr
secondli
rvrr
qar
sequenc
nearli
neg
qgr
fig
exogen
trypsin
unabl
cleav
rvrr
fig
also
enhanc
hcv
infect
find
suggest
endogen
transmembran
serin
proteas
furin
hpn
preferenti
cleav
qgr
rvrr
like
help
hcvcc
infect
similar
conclus
demonstr
human
liver
contain
load
activ
hcvcc
infect
vitro
serin
proteas
requir
earli
event
hcv
infectionhcv
entri
result
suggest
host
transmembran
serin
proteas
support
hcv
entri
cell
surfac
human
liver
cell
target
key
molecul
provir
infect
discoveri
provid
new
insight
antivir
strategi
author
name
bold
design
share
authorship
